Construction of a Fusion Peptide 5rolGLP-HV and Analysis of its Therapeutic Effect on Type 2 Diabetes Mellitus and Thrombosis in Mice

Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats

(2015) Mohamed A. Morsy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Comparative pharmacokinetics of arctigenin in normal and type 2 diabetic rats after oral and intravenous administration

(2015) Xiao-yan Zeng et al.   FITOTERAPIA

Insulin Resistance Associated Genes and miRNAs

(2014) Maryam Honardoost et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

Expression and Purification of Optimized rolGLP-1, A Novel GLP-1 Analog, in Escherichia Coli BL21(DE3) and its Good Glucoregulatory Effect on Type 2 Diabetic Mice

(2014) Baicheng Ma et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats

(2014) Can Liu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice

(2014) Rachael Lennox et al.   NEUROPHARMACOLOGY

High fat diet and GLP-1 drugs induce pancreatic injury in mice

(2014) Rodney Rouse et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Expression of rolGLP-HV in E. coli and its Dual-Function for the Treatment of Diabetes and Thrombosis

(2013) Yaofang Zhang et al.   International Journal of Peptide Research and Therapeutics

Glucagon-like peptide 1 and appetite

(2013) Megan J. Dailey et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Antioxidant Effect of Azadirachta Indica on High Fat Diet Induced Diabetic Charles Foster Rats

(2012) Atul Shrivastava et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

(2012) Edwin T. Parlevliet et al.   PLoS One

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

(2011) S. L. Samson et al.   DIABETOLOGIA

Cellular and molecular mechanisms of vascular injury in diabetes — Part I: Pathways of vascular disease in diabetes

(2011) Rosalinda Madonna et al.   VASCULAR PHARMACOLOGY

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

(2009) Mingming Gao et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

The impact of glucose-lowering therapy on cardiovascular outcomes

(2009) Eberhard Standl et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Glycaemic control in type 2 diabetes: Targets and new therapies

(2009) Abd A. Tahrani et al.   PHARMACOLOGY & THERAPEUTICS

Cardiovascular disease and heritability of the prothrombotic state

(2008) R.A. Ajjan et al.   BLOOD REVIEWS